Factors affecting the preparation of Cilnidipine nanoparticles

Authors

  • Ruaa Alzalzalee 1Ministry of Health and Environments, Al-Kut Hospital, Directorate, Wassit, Iraq
  • Hanan Kassab 2Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, Iraq.

DOI:

https://doi.org/10.31351/vol32issSuppl.pp235-243

Keywords:

Cilnidipine, Soloplus®, PVA cold, Poloxamers 188, PEG200, Glycerol

Abstract

Cilnidipine is a dihydropyridine calcium channel blocker used to improve the neurological outcome following subarachnoid hemorrhage. It belongs to BCS class II drugs that have a low oral bioavailability of 13%, thus preparation as nanoparticles would be expected to improve bioavailability.

The aim of the study is to prepare Cilnidipine as nanoparticles using different carriers and co-carriers, concentrations, and types.

Cilnidipine nanoparticles were prepared by a solvent anti-solvent method using different carriers (Soloplus®, Poloxamer 188, PVA cold) with co-stabilizers  (PEG200, glycerol) at different ratios.

Based on the obtained results, formula N4, which included Soloplus in a 1:1:1 weight ratio of drug to the polymer to co-stabilizer, exhibited a particle size of 88.89 nm when stirred at 1000 rpm with an injection speed of 1 ml/min. The polydispersity index (PDI) for this formula was measured at 0.2413. Furthermore, formula N4 demonstrated an impressive 92.2% drug content and an entrapment efficiency (EE) of 95.8%, giving 100% release in 30 min.

 

Author Biography

  • Hanan Kassab , 2Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, Iraq.

     

     

How to Cite

1.
Alzalzalee R, Kassab H. Factors affecting the preparation of Cilnidipine nanoparticles . Iraqi Journal of Pharmaceutical Sciences [Internet]. 2023 Nov. 3 [cited 2024 Dec. 23];32(Suppl.):235-43. Available from: https://bijps.uobaghdad.edu.iq/index.php/bijps/article/view/2671

Publication Dates

References

Reference

Saadh MJ, Jadullah RK. Nanotechnology in Drug Delivery. Pharmacologyonline. 2021;3:1129–35.

Konwar R, Ahmed AB. Nanoparticle: an Overview of Preparation, Characterization and Application. Int Res J Pharm. 2016;4(4):47–57.

Jafari M, Yousefi M, Baniyaghoub S. Original paper Green Synthesis and Characterization of AgCl Nanoparticle Using Onopordum acanthium Extract. 2022;1(3):154–8.

Shid RL, Dhole SN, Kulkarni N, Shid SL. Nanosuspension: A review. Int J Pharm Sci Rev Res. 2013;22(1):98–106.

Ainurofiq, A.; Putro, D.S.; Ramadhani, D.A.; Putra, G.M.; Santo, L.D.D. A review on solubility enhancement methods for poorly water-soluble drugs. J. Rep. Pharm. Sci. 2021, 10, 137–147.

Hoshide S, Kario K, Ishikawa J, Eguchi K, Shimada K. Comparison of the Effects of Cilnidipine and Amlodipine on Ambulatory Blood Pressure. 2005;28(12):1003–8.

Kokilambigai KS, Lakshmi KS. Innovare Academic Sciences Review Article Analytical Methodologies For Determination Of Cilnidipine : An Overview. 2014;6(6).

Mishra R, Mir SR, Amin S. Polymeric Nanoparticles For Improved Bioavailability of Cilnidipine. 2017;9(4).

Ministerial W, No N, Paragraph P, Law A, No L. The Ministry of Health , Labour and. Powder Diffr. 2007;2007(285):1–1654.

Upadhay M. Preparation and evaluation of cilnidipine microemulsion. In: Journal of Pharmacy and Bioallied Sciences. 2012. p. 114–5.

Liu Q, Mai Y, Gu X, Zhao Y, Di X, Ma X, Yang J. A wet-milling method for the preparation of cilnidipine nanosuspension with enhanced dissolution and oral bioavailability. Journal of Drug Delivery Science and Technology. 2020 Feb 1;55:101371.

Nagar SK, Soniwala MM. Optimization of Cilnidipine Nanosuspension Using a Center Composite Design. Int J Pharm Sci Drug Res. 2017;9(04):149–59.

Sh H, Rajab NA. Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation. Journal of Complementary Medicine Research. 2023 Feb 10;14(1):16-.

Jassim ZE, Hussein AA. Formulation and evaluation of clopidogrel tablet incorporating drug nanoparticles. IJPS. 2014:838-51.

Hazzaa SA, Abd-Alhameed SN. Formulation and Evaluation of Optimized Zaltoprofen Lyophilized Tablets by Zydis Technique. Iraqi Journal of Pharmaceutical Sciences (P-ISSN 1683-3597 E-ISSN 2521-3512). 2017 Jul 12;26(1):40-9.

Hussein ZA, Rajab NA. Formulation and characterization of bromocriptine mesylate as liquid self-nano emulsifying drug delivery system. Iraqi Journal of Pharmaceutical Sciences (P-ISSN 1683-3597 E-ISSN 2521-3512). 2018 Dec 6:93-101.

Ghareeb MM. Formulation and characterization of isradipine as oral nanoemulsion. Iraqi Journal of Pharmaceutical Sciences (P-ISSN 1683-3597 E-ISSN 2521-3512). 2020 Jun 25;29(1):143-53.

Rajab NA, Jassem NA. A Design and In vitro Evaluation of Azilsartan Medoxomil as A Self-Dispersible Dry Nanosuspension. Der Pharm Sin. 2018;9(1):12-32.

Rao S, Song Y, Peddie F, Evans AM. Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs. Int J Nanomedicine. 2011;6:1245–51.

Daebis N, Abdallah OY, El-Massik M, Abdelkader H. Formulation and Characterization of Itraconazole Oral Nanosuspension: Methyl Cellulose as Promising Stabilizer. J Drug Dev Clin Trials. 2015;1(1):1–8.

Jassem NA, Rajab NA. Formulation and in vitro evaluation of azilsartan medoxomil nanosuspension. Int J Pharm Pharm Sci. 2017;9(7):110.

Kim, M. S., Song, H. S., Park, H. J. and Hwang, S. J. Effect of solvent type on the nanoparticle formation of atorvastatin calcium by the supercritical antisolvent process. Chemical and Pharmaceutical Bulletin,2012; 60(4).

Alwan, R. M. and Rajab, N. A. Nanosuspensions of Selexipag: Formulation, Characterization, and in vitro Evaluation. Iraqi Journal of Pharmaceutical Sciences,2021; 30(1).

Dora CP, Singh SK, Datusalia AK, Deep A. Development and characterization of nanoparticles of glibenclamide by solvent displacement method. 2010; Acta Poloniae Pharmaceutica -Drug Research.2010; 67(3 ): 283-290.

Yang H, Teng F, Wang P, Tian B, Lin X, Hu X, et al. Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability. Int J Pharm. 2014;477(1–2):88–95.

Rashid AM, Abd-Alhammid SN. Formulation and characterization of itraconazole as nanosuspension dosage form for enhancement of solubility. Iraqi J Pharm Sci. 2019;28(2):124–33.

Shaikh F, Patel M, Patel V, Patel A, Shinde G, Shelke S, Pathan I. Formulation and optimization of Cilnidipine loaded nanosuspension for the enhancement of solubility, dissolution and bioavailability. Journal of Drug Delivery

Prajapati ST, Maheshwari PD, Patel CN. Formulation and Evaluation of Orodispersible Tablets of Cilnidipine By Spray Drying Technique. Shailesh al World J Pharm Pharm Sci. 2015;4(05):1526–39.

Downloads

Published

2023-11-03